Past Collaborations
My Services
Innovative consulting solutions to achieve impactful results

As a seasoned consultant for the pharmaceutical industry and an active member of multiple advisory boards, Dr. Isaacs provides strategic insights for cutting-edge diabetes solutions and ensures the highest standards in diabetes care.
As a seasoned consultant for the pharmaceutical industry and an active member of multiple advisory boards, Dr. Isaacs provides strategic insights for cutting-edge diabetes solutions and ensures the highest standards in diabetes care.
An authority in diabetes content
With over 80 peer reviewed publications, Dr. Isaacs stands as a leading authority in diabetes content.
Offering expert writing services, she has repeatedly transformed diabetes research and clinical practice insights into engaging manuscripts, reports, and educational materials.
Elevating diabetes care through compelling speaking engagements

Dr. Isaacs is renowned for her captivating speaking engagements that educate and inspire clinicians and patient advocates.
She has been a speaker for leading organizations including the American Diabetes Association, the Association of Diabetes Care and Education Specialists, the American Association of Clinical Endocrinology, and the American Heart Association.
In addition, she frequently delivers continuing medical education (CME) programs to equip providers with the latest knowledge and skills.
What I've Been Working on
Consulting
Speaking
Medical Writing
CME
My Expertise
Recent Presentations
Recent Publications
Recent Podcasts
Videos
X Timeline
What's new in diabetes technology?
Tune into the latest #DiabetesDialogue to learn about a pair of trials examining insulin delivery systems in adults with #Type2Diabetes.
@DianaMIsaacs @natalie_bellini
https://www.hcplive.com/view/diabetes-dialogue-omnipod-5-and-medtronic-780g-for-type-2-diabetes
📣 Perspective from @DianaMIsaacs:
"This confirms what we see in practice that Omnipod 5 (and other automated insulin delivery systems) work very well for people with type 2 #diabetes that need insulin."
@GoHealio
https://www.healio.com/news/endocrinology/20250214/automated-insulin-delivery-lowers-hba1c-improves-time-in-range-in-type-2-diabetes#EFE71645510B41F78A3E741F631A3635
Great news for people with T2D and CKD!
The FLOW trial was stopped early due to clear benefits for using semaglutide to reduce progression of kidney disease and cardiovascular death in people with #T2D at risk for progressive diabetic kidney disease @US_FDA @novonordiskus